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According to the World Health Organization, approximately
295,000womendied in 2017 during the antenatal and postpar-
tum period. The vast majority (94%) of these cases occurred in
low- and middle-income countries, with an estimate of 810
daily deaths frompreventable causes.1Obstetric hemorrhage is
the leading cause ofmaternal mortality worldwide and, among
its key etiologies, placenta accreta spectrum (PAS) disorders
havebeen increasing inprevalence concurrentlywith the global
rise in the proportion of Cesarean deliveries and rates have
currently being reported between 0.01% to 1.1% of pregnan-
cies.2–5 Accurate screening and diagnosis of PAS is of utmost
importancefor timelyantenatal referral to tertiaryhospitals and
management by specializedmultidisciplinary teams,which has
been associated with a reduction in its associated morbimor-
tality.6 Although ultrasound diagnosis of PAS can be reliably
done in centers with expertise, with an accuracy of approxi-
mately 90%,7,8 in non-specialized facilities this rate falls to 50%,
mainly due to insufficient clinical suspicion and/or knowledge
of risk factors.9,10 Therefore, effective and systematic screening
and diagnostic protocols for PAS should be implemented in all
maternal-fetal health care services in order to prevent adverse
outcomes related to undiagnosed PAS disorders. The purpose of
this article is to highlight the importance of basic questions that
should be incorporated by all sonographers while performing
routine obstetrical ultrasound to improve the detection of PAS.
What are the Relevant Risk Factors for Pas
Screening?
Numeroushistorical risk factors have been associated with
the occurrence of PAS, including maternal obesity, advanced
maternal age and parity, previous uterine surgery (includ-
ing illegal terminations of pregnancy), and use of assisted
reproductive technologies.11 However, there is no doubt
that the concomitance of the only risk factor related to the
ongoing pregnancy–a low-lying placenta–with a previous
Cesarean birth are the main risk factors for PAS, occurring
concurrently in more than 90% of confirmed cases.11–13 The
reasons for that are not difficult to understand. Although
preliminary studies suggested that PAS resulted from an
excessive trophoblastic invasion and/or substandard decid-
ual function,14,15 the hypothesis of placental implantation
on or into an iatrogenically defective decidua is currently
gaining acceptance,16–18 making the case for a common
pathophysiological pathway between development of an
uterine niche, Cesarean scar pregnancy (CSP) and PAS.
Furthermore, recent epidemiological studies have chal-
lenged the previous association of the number of previous
Cesarean sections and the risk for PAS, confirming that
there is a plateau of risk for PAS after the second Cesarean
birth.19,20 This can be explained by the higher position of a
uterine niche after previous elective Cesarean section com-
pared to emergency Cesarean birth resulting in a three-fold
increased risk of developing PAS in future pregnancies
with placenta previa.19,21 Therefore, as most risk factors
for PAS seem to be proxy markers for the two previously
cited and in order to improve the identification of PAS cases
in the antenatal period, we would like to emphasize the
importance of asking two simple questions while perform-
ing every obstetrical ultrasound: “is the placenta low-
lying?” and “did the patient have a previous Cesarean
section?”.
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Is First Trimester Ultrasound Screening for
Paspossible?
If the answer is yes to the latter two questions, then it is
indeed possible that the woman may have a PAS. As obstet-
rical ultrasound between 11 and 13 gestational weeks is
conventionally performed for pregnancy dating, identifica-
tion of multiple pregnancies, diagnosis of abnormalities and
screening for trisomies and preeclampsia, this would be the
perfect timing to firstly assess the risk for PAS disorders.
Several ultrasoundmarkers have been proposed, such as low
implantation of gestational sac on or into a previous Cesare-
an scar, reduced myometrial thickness, placental lacunae,
enhancedmyometrial vascularity and abnormal uterus-blad-
der interface, many of them in common with the diagnostic
features of a CSP (►Figure 1). A 2018 systematic review and
meta-analysis22 concluded that at least one PAS sign can be
identified during the first trimester in 91.4% of confirmed
cases and that a low anterior implantation of the gestational
sac or the placenta close to orwithin a previous Cesarean scar
is the most commonly observed sign (82.4% of cases), with a
sensitivity of 44.4% (95% CI, 21.5-69.2%) and a specificity of
93.4% (95% CI, 90.5%-95.7). In 2019, a prospective screening
study23 assessed the performance of a two-stage PAS screen-
ing strategy in 22,604 pregnancies. Patients were first eval-
uated between 11-13 weeks and those presenting low-lying
placenta and a history of uterine surgery were referred to a
specialized clinic at 12-16 weeks. For the 6% (1298 cases) of
pregnant womenwith at least one marker and considered to
be at high-risk, the diagnosis of PASwas suspected in 14 cases
and confirmed in 13. There were no cases of PAS in the low-
risk patients. Performance of screening was not assessed due
to the low number of PAS cases. These findings support the
relevance of being aware of the position of the gestational
sac/placenta in the first trimester scan in patients with a
history of Cesarean sections, especially for the high-posi-
tioned scars secondary to elective procedures. On the one
hand, the first trimester diagnosis of a CSP/PAS is desirable
and should be pursued, mainly for being a condition associ-
atedwith increasedmaternalmorbimortalitywith a need for
referral to specialized multidisciplinary centers for appro-
priate counselling andmanagement.24On the other, thisfirst
trimester screening strategy would label 6% of women as
being at high-risk for PAS, resulting in additional expendi-
ture, use of human and logistical resources, and the negative
psychological burden on the family –with less than 1 in 100
of these ’high-risk’ women actually having a PAS. Addition-
ally, although termination of pregnancy is usually discussed
with these families, the natural history of CSP is not yet fully
understood. Recent studies tried to discriminate the out-
comes of CSP based on ultrasound signs. Among them,
placental implantation “in the niche” instead of “on the
scar”,25 residual myometrial thickness below 2mm,25 and
identification of the pregnancy in the “high-risk-for-PAS
triangle”,26 would be predictive of worse surgical outcomes
and more advanced third-trimester sonographic staging of
PAS (►Figure 1A). However, the rarity of this condition
precludes the assessment of strong associations with out-
come from the previous studies. Therefore, it is imperative to
establish a collaborative approach to gather global experi-
ence among specialists conducting CSP cases. With this
purpose in mind, we encourage clinician to upload CSP cases
onto the international CSP Registry (https://csp-registry.
com) (►Figure 1B).
Contingent Second and Third Trimester
Screening for Pas
The rationale for a mid-trimester screening for PAS is to take
advantage of the conventional 18-23 weeks anatomical
ultrasound evaluation and the already implemented screen-
ing for placenta previa in non-specialized facilities. With the
two proposed questions in mind, upon identification of a
low-lying placenta (first question) on routine mid-trimester
scan, all sonographers should enquire the patient about a
previous Cesarean section (second question). The order of
these questions is extremely important for the feasibility of
the screening program, as the proportion of patients with
Fig. 1. A. Sagittal first trimester transabdominal ultrasound image of a Cesarean scar pregnancy highlighting the “high-risk-for-placenta accreta
spectrum triangle” (implantation on the lower anterior quarter of the uterus, and into the Cesarean scar niche); B. Sagittal third trimester
transabdominal ultrasound image of a placenta accreta spectrum disorder on a placenta previa completely covering the cervical internal os
(arrow).
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previous uterine surgery is incomparably higher than those
with persistent low-lying placenta in the third trimester. This
strategy has been explored by a retrospective study encom-
passing 57,179 women scanned between 18-23 gestational
weeks.27 For the 7.8% of patients with a low-lying placenta, a
32 week scanwas arranged to assess placental position. Only
220 (0.4%) had a diagnosis of persistent placenta previa. 75
(0.1%) of them had a previous uterine surgery and were
therefore referred for assessment by the PAS diagnostic
service. In total, 21 out of 22 PAS cases were correctly
identified by this screening program, with a sensitivity of
95.45% (95% CI, 77.16-99.88%) and a specificity of 100% (95%
CI, 99.07-100%) (►Figure 2). PAS was confirmed based on
clinical and histopathological criteria, as recommended by
the International Federation of Gynecology and Obstetrics
(FIGO).28 From a public health perspective, this contingent
PAS screening strategy is feasible in lower-resource medical
settings with basic obstetric ultrasound facilities, not requir-
ing additional visits beyond those that are routinely indicat-
ed. Furthermore, comparing to the first trimester screening,
only 0.1% of patients would need to be referred to a special-
ized PAS diagnostic service (with one in three having a
confirmed PAS), as opposed to a 6% figure between 11-13
weekswith less than one in 100 subsequently diagnosedwith
PAS. The success of such a screening strategy relies on an
established regional referral service, with access to fetal
medicine specialists properly trained to diagnose PAS dis-
orders and dedicated, highly specialized multidisciplinary
team at tertiary level hospital, where safe delivery can be
arranged.29
Two simple questions asked by the sonographer at every
obstetric ultrasound examination have the potential to alter
the course of pregnancies at risk for PAS: (1) “is the placenta
low-lying?” and (2) “did the patient have a previous cesarean
section?”. Suspicionfor CSP during the first trimester scan
should trigger referral to specialized centers and careful
counselling taking into consideration the lack of data regard-
ing the natural history of CSP. Contingent screening for PAS in
womenwith persistent placenta previa in the third trimester
and a history of previous Cesarean section is feasible, effec-
tive and does not put additional burden on the public health
system. In parallel with the establishment of specialist
referral centers, the implementation of these simple ques-
tions and screening strategy have the potential to improve
antenatal PAS detection rates and decrease maternal mor-
bidity and mortality secondary to undiagnosed PAS.
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